SCHEMBL5311543

SCHEMBL5311543

COCCOc1ccc(S)cc1

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
RECQL P46063 1/20 0.44
MAPT P10636 2/20 0.44
RAB9A P51151 1/20 0.39
NQO1 P15559 1/20 0.39
PKM P14618 1/20 0.38
ACACB O00763 1/20 0.38
PRSS1 P07477 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
MAOA P21397 1/20 0.36
DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17178366 0.94 KDM4E (0.53) KDM4ERECQLMAPTL3MBTL1
SCHEMBL21564102 0.94 KDM4E (0.53) KDM4ERECQLMAPTL3MBTL1
SCHEMBL12939845 0.89 L3MBTL1 (0.40) KDM4ERECQLMAPTACACBPRSS1
SCHEMBL7042525 0.88 PRSS1 (0.44) KDM4ERECQLMAPTNQO1PKM
SCHEMBL8339774 0.88 MAPT (0.52) KDM4ERECQLMAPTRAB9ANQO1
SCHEMBL15586360 0.82 KDM4E (0.49) KDM4ERECQLMAPTRAB9ANQO1
SCHEMBL6883170 0.82 KDM4E (0.44) KDM4ERECQLMAPTRAB9ANQO1
SCHEMBL12703538 0.81 KDM4E (0.61) KDM4ERECQLMAPTL3MBTL1
SCHEMBL12093635 0.81 CA12 (0.55) KDM4EMAPTRAB9AL3MBTL1
SCHEMBL13554406 0.81 CYP3A4 (0.50) KDM4ERECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12032288-B2 Actinic ray-sensitive or radiation-sensitive resin composition, resist film, pattern forming method, and method for manufacturing electronic device FUJIFILM CORPORATION (JP) 2024-07-09 US disclosed
US-10890847-B2 Pattern forming method, resist pattern, method for manufacturing electronic device, and electronic device FUJIFILM CORPORATION (JP) 2021-01-12 US disclosed
US-20170075222-A1 PATTERN FORMING METHOD, RESIST PATTERN, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2017-03-16 US disclosed
US-20120252741-A1 NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS BIOMARIN PHARMACEUTICAL INC. (US) 2012-10-04 US disclosed
US-20120252741-A1 NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS BIOMARIN PHARMACEUTICAL INC. (US) 2012-10-04 US disclosed
US-20100105607-A1 NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS LEAD THERAPEUTICS, INC. (US) 2010-04-29 US disclosed
US-20100105607-A1 NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS LEAD THERAPEUTICS, INC. (US) 2010-04-29 US disclosed
WO-2007048064-A2 AMINO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed
WO-2007048064-A2 AMINO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105607-A1 NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS ASNS, ALG8, ALG1 KDM4E 934/4885RECQL 4408/4885MAPT 4760/4885
US-20120252741-A1 NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS ASNS, DNPEP, ALG8 KDM4E 701/4885RECQL 4529/4885MAPT 4598/4885
US-12032288-B2 Actinic ray-sensitive or radiation-sensitive resin composition, resist film, pattern forming method, and method for manufacturing electronic device RER1, COL1A1, RAD51 KDM4E 3311/4885RECQL 125/4885MAPT 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.